GENEVA, January 8. /TASS/. The World Health Organization (WHO) plans to receive the complete data about the coronavirus vaccine developed by Russia’s Gamaleya National Research Institute of Epidemiology and Microbiology by the end of this month, Assistant Director-General Mariangela Simao told a briefing on Friday.

"In the case of new vaccines, we do an Emergency Use Listing assessment. We have received 13 valid proposals since October. Besides the Pfizer vaccine that was already listed by WHO, we do have other products at an advanced stage," she said.

"We have received, for example, the information from Sinopharm, we have finalized that in phase three trial and it is being authorized in some countries. We are in the process of receiving the complete data from AstraZeneca. And we expect to receive additional data from the Gamaleya Center, a Russian producer, before the end of January," Assistant Director-General said.

"This is just to say that these products are currently being assessed by WHO and this is important, not only because many countries rely on WHO’s assessment for authorizing the use of the product in their own countries but also because it helps international procurers like UNICEF and other to procure the vaccines that have been assessed by WHO," she noted.

Registered by Russia on August 11, 2020, Sputnik V developed by the Gamaleya National Research Center of Epidemiology and Microbiology became the world’s first coronavirus vaccine. Interim research results demonstrate that the efficacy of the Sputnik V vaccine exceeds 95% on the 42nd day after the first dose, provided that a patient receives the second dose three weeks after the first one.

Requests for more than 1.2 bln doses of Sputnik V vaccine have come from more than 50 countries. The vaccine supplies for the global market will be produced by international partners of Russian Direct Investment Fund in India, Brazil, China, South Korea and other countries.